Natural Senolytic Supplements: Quercetin, Fisetin, DHM — Evidence Compared

Senolytics — compounds that selectively eliminate senescent cells — are one of the most evidence-supported anti-aging intervention categories in current research. Three natural compounds have accumulated meaningful evidence: quercetin, fisetin, and (as of 2026) DHM.

Here’s how their evidence compares, what makes their mechanisms complementary rather than redundant, and the practical protocol questions researchers are still working out.

Educational content. Not medical advice.

---

Why Natural Senolytics (vs. Pharmaceutical)

The most potent senolytics are pharmaceutical: navitoclax (ABT-263), dasatinib. These are cancer drugs being repurposed for aging biology. They have meaningful side effects (navitoclax causes platelet depletion; dasatinib has immunosuppressive effects) that limit their use outside clinical trials.

Natural compounds offer a different profile: lower potency, cleaner side effect profiles, accessible as supplements. The trade-off is that natural senolytics likely have less complete senescent cell clearance per dose than pharmaceutical senolytics — but for healthy adults pursuing longevity rather than treating established age-related disease, the risk-benefit math is different.

The current research trajectory: natural senolytics as maintenance/prevention, pharmaceutical senolytics as therapeutic interventions in established disease.

---

Quercetin

Source: Onions, capers, apples, berries — one of the most abundant flavonoids in the human diet.

Mechanism: Quercetin inhibits Bcl-2 and Bcl-xL — anti-apoptotic proteins that are upregulated in senescent cells. Senescent cells use these proteins to resist the cell death signals that would normally clear them. By inhibiting Bcl-2/Bcl-xL, quercetin restores the sensitivity to apoptosis that senescent cells have lost.

Evidence:

Preclinical: Quercetin + dasatinib was the first senolytic combination identified in the Kirkland lab (Mayo Clinic) research that launched the field. Together, they clear senescent cells in multiple mouse tissues and extend healthspan in aged mice.

Human (Tier 1): The first human senolytic trial (Justice et al., 2019) used quercetin 1,000mg + dasatinib 100mg in patients with idiopathic pulmonary fibrosis (IPF). Results: reduced senescent cell burden in adipose tissue (measured by biopsy), and improvements in physical function tests (6-minute walk distance). This is Tier 1 human evidence for senescent cell clearance in humans.

Important caveat: The human evidence used quercetin combined with dasatinib — a pharmaceutical. Quercetin’s standalone senolytic potency in humans hasn’t been separately established at the same level.

Dose: 500–1,000mg quercetin in senolytic protocols. Often used with fisetin for natural senolytic stacking.

Bioavailability issue: Standard quercetin has poor oral bioavailability. Quercetin phytosome (complexed with phospholipids) or quercetin from sophora japonica have better absorption. This matters for dose calculations.

---

Fisetin

Source: Strawberries, apples, persimmons — a flavonol found in various fruits and vegetables at low concentrations. Most fisetin supplements are synthetic or from Rhus succedanea bark.

Mechanism: Multiple pathways. Fisetin has Bcl-2 inhibitory activity similar to quercetin, plus additional effects on mTOR signaling and AMPK activation. It also has potent anti-inflammatory activity via NF-κB inhibition.

Evidence:

Preclinical: The Kirkland lab’s landmark 2018 EBioMedicine study tested 10 flavonoids for senolytic activity. Fisetin had the highest senolytic potency of any natural compound tested. In aged mice, fisetin extended both median and maximum lifespan, reduced senescent cell burden in multiple tissues, and improved multiple health parameters (physical function, cognitive markers, reduced inflammation).

Human (Tier 1, early): Small human studies in frail elderly and COVID-19 patients have been conducted. Results show reduction in inflammatory markers but haven’t yet demonstrated direct senescent cell clearance with the same rigor as the quercetin/dasatinib IPF trial. Larger Phase 2 trials ongoing.

Dose: Preclinical studies used fisetin at 20mg/kg (mouse), which extrapolates to roughly 100–200mg/day in humans. Many supplement protocols use 100–500mg/day. Note: fisetin has poor oral bioavailability; fat-soluble formulations or novel delivery formats perform better.

---

DHM (Dihydromyricetin) — The 2026 Entry

Source: Hovenia dulcis (Japanese raisin tree) seed and fruit extract.

Mechanism: A third, distinct pathway from quercetin/fisetin. The March 2026 Nature Communications study identified DHM as a senolytic via PRDX2 binding — peroxiredoxin-2, a cytoplasmic thiol-dependent peroxidase involved in cellular redox sensing.

PRDX2 regulates the redox state of cytoplasmic proteins and acts as a sensor for oxidative stress. Senescent cells, which have elevated oxidative stress, are particularly vulnerable to PRDX2-targeting interventions. DHM’s binding to PRDX2 triggers a senolysis cascade different from Bcl-2 pathway inhibition.

Evidence:

Murine models (Tier 3): DHM reduced cardiac fibrosis, neuroinflammation markers, and improved physical performance metrics in aged mice. The PRDX2 mechanism was validated by PRDX2 knockout experiments — mice without PRDX2 showed no senolytic response to DHM.

Human liver data (Tier 1): The 2026 MASLD RCT in humans showed measurable liver health improvement at 300mg/day over 12 months. While this was conducted for liver health endpoints rather than senolytic endpoints, the senolytic mechanism is likely contributing — senescent hepatic stellate cells drive liver fibrosis, and the study’s liver stiffness improvement (6.3 → 5.3 kPa) may partially reflect senescent cell clearance in liver tissue.

Why DHM Adds to the Stack:

The PRDX2 mechanism is genuinely different from quercetin/fisetin’s Bcl-2 pathway. Different target proteins mean potentially:

• Clearance of senescent cell populations that quercetin/fisetin might miss
• Additive rather than redundant effects in combination
• Different tissue distribution (DHM has particular affinity for liver tissue, which is why the liver data exists)

Additionally, DHM is the only senolytic with:

• Human clinical trial data with liver biomarker endpoints
• A concurrent established use case (alcohol metabolism support) making it a logical daily supplement
• A clean 12-month safety profile from a human trial in a vulnerable population

→ DHM Senolytic Study Full Breakdown →

---

Evidence Comparison

Compound	Human Tier 1	Animal Tier 3	Mechanism	Bioavailability
Quercetin	✅ (with dasatinib)	✅ multiple	Bcl-2/Bcl-xL inhibition	Poor oral; phytosome better
Fisetin	Emerging	✅ strong (lifespan)	Bcl-2 + mTOR + AMPK	Poor oral; fat-soluble better
DHM	✅ liver biomarkers	✅ (2026)	PRDX2 binding	Moderate; fat-soluble preferred
Navitoclax	✅	✅	Bcl-2/Bcl-xL inhibition	Pharmaceutical (N/A)

---

Senolytic Stack Design

Because quercetin/fisetin and DHM target different pathways, stacking them is rationally justified — they’re not competing for the same mechanism.

A natural senolytic stack:

• Quercetin phytosome 500–1,000mg
• Fisetin 100–500mg (fat-soluble formulation)
• DHM 300–1,000mg

Pulsed dosing protocol:

• 2–3 consecutive days on
• 3–6 weeks off
• Repeat quarterly or as desired

This pulsed approach mirrors the clinical protocols being studied. Continuous daily senolytic dosing isn’t the current approach — you want a clearance event followed by recovery time, not chronic low-level senolytic pressure.

Exception for DHM: Given DHM’s dual role as a daily liver support supplement (300mg/day has liver health benefits demonstrated in the MASLD RCT), daily DHM use at 300mg makes sense for liver health and metabolism even outside of a senolytic pulsing protocol. Increase to 500–1,000mg during senolytic pulse cycles.

---

What to Expect (Realistically)

Senolytic supplementation is not an acutely perceptible intervention. You’re not going to feel your senescent cells being cleared. The expected outcomes are long-term:

• Reduced chronic inflammation (may improve energy, recovery)
• Better organ function maintenance over years
• Potentially reduced risk of age-related diseases

The honest benchmark: this is supplementation for people who are thinking about 10-year health trajectories, not people looking for immediate symptom relief.

The most useful current signal that it’s doing something: periodic measurement of inflammatory biomarkers (hs-CRP, IL-6 if accessible) and direct senescence markers if you have access to research labs or comprehensive longevity clinics.

---

The Bottom Line

Quercetin, fisetin, and DHM are the three natural compounds with the most credible senolytic evidence. They address different molecular targets, making combination use rationally justified rather than redundant.

Of the three, DHM is uniquely positioned as a multipurpose supplement — senolytic, liver health, and alcohol metabolism mechanisms make it relevant daily rather than only in pulsed longevity protocols.

→ Longevity Supplements Hub → → Senescent Cells: What They Are and Why They Drive Aging → → DHM Senolytic: Full Mechanism Breakdown → → DHM Liver Health →

---

Hovenia is a Canadian supplement company. Products are not intended to diagnose, treat, cure, or prevent any disease. This content does not constitute medical advice. This statement has not been evaluated by the FDA or Health Canada.